AKBA

Q: What is the price of Akebia Therapeutics (AKBA) today?

The price of Akebia Therapeutics (AKBA) today is $ 1.66, with return of -10.27% compared to the last year. The price of Akebia Therapeutics (AKBA) started the year trading around $ 1.90 and today it is at $ 1.66. Follow the real-time price chart, the historical price of Akebia Therapeutics (AKBA) and international markets.

Q: When does Akebia Therapeutics (AKBA) pay dividends?

Akebia Therapeutics (AKBA) did not distribute dividends in the last year.

Q: Is Akebia Therapeutics (AKBA) worth it?

Currently, Akebia Therapeutics (AKBA) is priced at $ 1.66, with a P/E of -25.67%, representing a deviation of -773% from its historical average P/E. In the last year, the stock showed a variation of -10.27 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was -10.27%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Akebia Therapeutics (AKBA) stock?

Investing in stocks of Akebia Therapeutics (AKBA) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Akebia Therapeutics (AKBA) yield today?

The yield of Akebia Therapeutics (AKBA) was -5.68% in the last month, -10.27% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Akebia Therapeutics (AKBA) today, the total investment would be $ 166.00, based on the current price of $ 1.66.If past performance were to repeat, the return on your investment would be:In 1 year: $ 148.95In 5 years: $ 166.00In 10 years: $ 166.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Akebia Therapeutics Inc.

Price

$ 1.66

return (12m)

-10.27%

p/e

-25.67

p/bv

9.81

DIVIDEND YIELD

0.00%

price AKBA

AKBA

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of AKBA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-5.68%

3 months

-43.73%

1 year

-10.27%

2 years

46.90%

5 years

0.00%

10 years

0.00%

Fundamentals AKBA

review the fundamentals of Akebia Therapeutics shares

P/E

-25.67

Sector: -3.74 Industry: -3.74

P/SALES RATIO (PSR)

1.81

Sector: -3.71 Industry: -3.71

P/BV

9.81

Sector: 2.05 Industry: 2.05

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-4.37%

Sector: -63.91% Industry: -63.91%

ROE

-38.23%

Sector: -67.36% Industry: -67.36%

ROIC

5.32%

Sector: -1,129.15% Industry: -1,129.15%

NET MARGIN

-7.06%

Sector: -41.63% Industry: -41.63%

GROSS MARGIN

78.98%

Sector: 39.39% Industry: 39.39%

OPERATING MARGIN

7.88%

Sector: -41.51% Industry: -41.51%

P/EBITDA

19.21

Sector: -3.78 Industry: -3.78

P/EBIT

37.34

Sector: -3.91 Industry: -3.91

P/ASSET

1.12

Sector: 1.49 Industry: 1.49

BVPS

0.16

Sector: 1.73 Industry: 1.73

EPS

-0.06

Sector: -2.05 Industry: -2.05

EQUITY RATIO

0.11

Sector: 0.41 Industry: 0.41

CAGR REVENUE 5 YEARS

-5.29%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-47.09%

Sector: - Industry: -

Fundamentals AKBA

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	19.36	0.00	0.00%	2.52%	$ 486.25 B	27.26%
PFE	15.06	1.59	10.56%	6.61%	$ 147.98 B	15.65%
ABBV	168.68	-154.98	-91.88%	2.88%	$ 402.80 B	4.00%
NVO	13.80	7.96	57.70%	3.53%	$ 212.69 B	32.78%
MRK	13.09	0.00	0.00%	3.25%	$ 249.10 B	29.63%
AZN	29.76	6.09	20.45%	1.74%	$ 279.74 B	16.17%
BMY	17.58	5.71	32.47%	4.76%	$ 106.18 B	12.57%
GILD	18.58	7.02	37.80%	2.59%	$ 150.68 B	27.88%
ZTS	19.83	9.74	49.11%	1.69%	$ 52.56 B	28.21%
HALO	12.44	14.70	118.17%	0.00%	$ 7.41 B	47.91%
REGN	16.32	2.41	14.79%	0.49%	$ 74.71 B	32.13%
AMGN	25.34	18.45	72.82%	2.85%	$ 177.48 B	19.47%
VRTX	31.73	6.73	21.22%	0.00%	$ 116.60 B	31.35%
MCK	24.84	-173.31	-697.75%	0.37%	$ 100.18 B	1.04%
CAH	29.67	-17.33	-58.40%	1.02%	$ 47.32 B	0.68%
ADMA	22.65	11.00	48.57%	0.00%	$ 4.74 B	42.87%
BIIB	16.57	1.46	8.83%	0.00%	$ 26.65 B	15.98%
HRMY	12.44	2.77	22.24%	0.00%	$ 2.31 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

AKBA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT THE COMPANY Akebia Therapeutics

Akebia Therapeutics Inc.

Average user rating I10

4.0 (0 people)

United States

18 years

Founded: 2007

2014

Time since IPO - 11 years

380

Employees

The Company Akebia Therapeutics Inc. (United States), is listed on Nasdaq with a market value of $ 408.10 Millions, having an equity of $ 41.59 Millions.

With a total of 380 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 225.08 Millions, which generated a profit in the amount of $ -15.90 Millions.

As for its main indicators, the Company has a P/E ratio of -25.67, a P/BV ratio of 9.81 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker AKBA.

Market cap

$ 408.10 Millions

Net worth

$ 41.59 Millions

US$ 41,590,000.00

Assets

$ 364.15 Millions

US$ 364,150,000.00

Total Shares Outstanding

265.00 Millions

265,000,000

Average Daily Trading Volume

$ 4.39 Millions

US$ 4,385,698.00

Sector

Health Care

Industry

Biotechnology

AKBA

AKBA revenue and profits

Financial Results AKBA

DRAG THE FRAME TO SEE MORE DATA

AKBA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 813.80 41,98% (12M)

P/E

24.84

0.37%

ROE

-697.75%

P/BV

-173.31

CAH - Cardinal Health

$ 198.18 70,66% (12M)

P/E

29.67

1.02%

ROE

-58.40%

P/BV

-17.33

JNJ - Johnson & Johnson

$ 211.58 48,72% (12M)

P/E

19.36

2.52%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 100.30 2,85% (12M)

P/E

13.09

3.25%

ROE

0.00%

P/BV

0.00

PFE - Pfizer

$ 25.85 9,78% (12M)

P/E

15.06

6.61%

ROE

10.56%

P/BV

1.59

ABBV - AbbVie

$ 223.32 34,34% (12M)

P/E

168.68

2.88%

ROE

-91.88%

P/BV

-154.98

AZN - AstraZeneca

$ 89.83 37,80% (12M)

P/E

29.76

1.74%

ROE

20.45%

P/BV

6.09

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 813.80 41,98% (12 M)

P/L

24.84

0.37%

ROE

-697.75%

P/VP

-173.31

CAH - Cardinal Health

$ 198.18 70,66% (12 M)

P/L

29.67

1.02%

ROE

-58.40%

P/VP

-17.33

JNJ - Johnson & Johnson

$ 211.58 48,72% (12 M)

P/L

19.36

2.52%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 100.30 2,85% (12 M)

P/L

13.09

3.25%

ROE

0.00%

P/VP

0.00

PFE - Pfizer

$ 25.85 9,78% (12 M)

P/L

15.06

6.61%

ROE

10.56%

P/VP

1.59

ABBV - AbbVie

$ 223.32 34,34% (12 M)

P/L

168.68

2.88%

ROE

-91.88%

P/VP

-154.98

AZN - AstraZeneca

$ 89.83 37,80% (12 M)

P/L

29.76

1.74%

ROE

20.45%

P/VP

6.09

Frequently Asked Questions

What is the price of Akebia Therapeutics (AKBA) today?

The price of Akebia Therapeutics (AKBA) today is $ 1.66, with return of -10.27% compared to the last year. The price of Akebia Therapeutics (AKBA) started the year trading around $ 1.90 and today it is at $ 1.66. Follow the real-time price chart, the historical price of Akebia Therapeutics (AKBA) and international markets.

When does Akebia Therapeutics (AKBA) pay dividends?

Akebia Therapeutics (AKBA) did not distribute dividends in the last year.

Is Akebia Therapeutics (AKBA) worth it?

Currently, Akebia Therapeutics (AKBA) is priced at $ 1.66, with a P/E of -25.67%, representing a deviation of -773% from its historical average P/E. In the last year, the stock showed a variation of -10.27 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was -10.27%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Akebia Therapeutics (AKBA) stock?

Investing in stocks of Akebia Therapeutics (AKBA) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Akebia Therapeutics (AKBA) yield today?

The yield of Akebia Therapeutics (AKBA) was -5.68% in the last month, -10.27% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Akebia Therapeutics (AKBA) today, the total investment would be $ 166.00, based on the current price of $ 1.66.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 148.95
In 5 years: $ 166.00
In 10 years: $ 166.00

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

AKBA

Akebia Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return of AKBA

review the fundamentals of Akebia Therapeutics shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY RATIO

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT THE COMPANY Akebia Therapeutics

Akebia Therapeutics Inc.

United States

18 years

2014

380

PROFIT X PRICE AKBA

Financial Results AKBA

AKBA cash flow

asset growth - AKBA

AKBA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

Frequently Asked Questions